TCA
AZN icon

Transcend Capital Advisors’s AstraZeneca AZN Stock Holding History

Transcend Capital Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.47M Sell
7,476
-124
-2% -$23.9K 0.12% 168
2025
Q4 		$1.4M Sell
7,600
-687
-8% -$120K 0.11% 173
2025
Q3 		$1.27M Sell
8,287
-851
-9% -$129K 0.09% 208
2025
Q2 		$1.28M Sell
9,138
-17,308
-65% -$2.43M 0.1% 186
2025
Q1 		$3.89M Sell
26,446
-9,864
-27% -$1.43M 0.28% 82
2024
Q4 		$4.76M Sell
36,310
-2,699
-7% -$378K 0.34% 65
2024
Q3 		$6.08M Buy
39,009
+53
+0.1% +$8.55K 0.41% 56
2024
Q2 		$6.08M Buy
38,956
+28,198
+262% +$4.24M 0.44% 48
2024
Q1 		$1.46M Buy
+10,758
New +$1.42M 0.12% 182
2023
Q3 		– Sell
-1,484
Closed -$212K – 492
2023
Q2 		$212K Sell
1,484
-127
-8% -$18.7K 0.02% 449
2023
Q1 		$224K Sell
1,611
-612
-28% -$82.3K 0.02% 426
2022
Q4 		$301K Sell
2,223
-208
-9% -$26.1K 0.03% 362
2022
Q3 		$267K Sell
2,431
-393
-14% -$49.9K 0.03% 385
2022
Q2 		$373K Buy
2,824
+101
+4% +$13.3K 0.04% 342
2022
Q1 		$361K Buy
2,723
+69
+3% +$8.28K 0.03% 372
2021
Q4 		$309K Buy
2,654
+388
+17% +$45.7K 0.03% 381
2021
Q3 		$282K Sell
2,266
-3
-0.1% -$349 0.03% 387
2021
Q2 		$271K Sell
2,269
-1,194
-34% -$131K 0.04% 271
2021
Q1 		$346K Buy
3,463
+846
+32% +$85K 0.04% 290
2020
Q4 		$262K Buy
+2,617
New +$277K 0.03% 313

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Transcend Capital Advisors's AZN Position: Q1 2026 in Review

Transcend Capital Advisors reduced its AstraZeneca (AZN) stake by 1.6% in Q1 2026, selling an estimated $23.9K and leaving 7,476 shares worth $1.47M. The position accounts for 0.12% of the portfolio, ranked #168.

Transcend Capital Advisors first reported a position in AZN in Q4 2020 and has held it in 20 quarters since. The position peaked at $6.08M in Q3 2024. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Transcend Capital Advisors held 7,476 shares of AstraZeneca worth $1.47M as of Q1 2026.
  • Transcend Capital Advisors sold 124 AstraZeneca shares in Q1 2026, an estimated $23.9K.
  • AstraZeneca made up 0.12% of Transcend Capital Advisors's portfolio in Q1 2026, its #168 holding.
  • Transcend Capital Advisors first reported a position in AstraZeneca in Q4 2020 and has held it in 20 quarters since.
  • Transcend Capital Advisors's AstraZeneca position peaked at $6.08M in Q3 2024.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Transcend Capital Advisors's 13F filing for Q1 2026, filed 13 May 2026.